How much does it cost to boot­strap a gene ther­a­py start­up? Not too much if you're Jim Wil­son, per Pas­sage Bio's $125M IPO fil­ing

Days ago when Deer­field part­ner Bruce Gold­smith jumped to helm Pas­sage Bio, he cit­ed a few rea­sons why it’s an “ex­treme­ly ex­cit­ing time” to be join­ing the gene ther­a­py play­er: IND fil­ings for three lead pro­grams, a da­ta-rich 2021 and an ex­pand­ing pipeline of ex­per­i­men­tal drugs for rare, mono­genic CNS dis­eases.

It turns out there’s one more rea­son he held back: The Philadel­phia-based start­up was prep­ping an IPO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER